RESEARCH QUESTIONS

1. What is the clinical effectiveness of fecal bacteriotherapy for adult patients with recurrent *Clostridium difficile* infection?

2. What are the evidence-based guidelines regarding the use of fecal bacteriotherapy for adult patients with *Clostridium difficile* infection?

3. What is the cost-effectiveness of fecal bacteriotherapy for adult patients with recurrent *Clostridium difficile* infection?

KEY MESSAGE

Five systematic reviews, one randomized controlled trial, five non-randomized studies, two evidence-based guidelines, and two economic studies were identified regarding fecal bacteriotherapy for adult patients with recurrent *Clostridium difficile*.

METHODS

This report updates the clinical literature search conducted for a previous March 2013 CADTH report with an additional new economic search on the topic. Both searches were conducted on key resources including PubMed, The Cochrane Library, University of York Centre for Reviews and Dissemination (CRD) databases, Canadian and major international health technology agencies, as well as a focused Internet search. No filters were applied to limit the retrieval by study type for the clinical search however an economic methodological filter was applied to the economic search. Where possible, retrieval for both searches was limited to the human population and English language documents. The clinical search was also limited to documents published between January 1, 2013 and March 28, 2014 while the economic search was limited to documents published between January 1, 2009 and March 28, 2014.

Disclaimer: The Rapid Response Service is an information service for those involved in planning and providing health care in Canada. Rapid responses are based on a limited literature search and are not comprehensive, systematic reviews. The intent is to provide a list of sources of the best evidence on the topic that CADTH could identify using all reasonable efforts within the time allowed. Rapid responses should be considered along with other types of information and health care considerations. The information included in this response is not intended to replace professional medical advice, nor should it be construed as a recommendation for or against the use of a particular health technology. Readers are also cautioned that a lack of good quality evidence does not necessarily mean a lack of effectiveness particularly in the case of new and emerging health technologies, for which little information can be found, but which may in future prove to be effective. While CADTH has taken care in the preparation of the report to ensure that its contents are accurate, complete and up to date, CADTH does not make any guarantee to that effect. CADTH is not liable for any loss or damages resulting from use of the information in the report.

Copyright: This report contains CADTH copyright material and may contain material in which a third party owns copyright. This report may be used for the purposes of research or private study only. It may not be copied, posted on a web site, redistributed by email or stored on an electronic system without the prior written permission of CADTH or applicable copyright owner.

Links: This report may contain links to other information available on the websites of third parties on the Internet. CADTH does not have control over the content of such sites. Use of third party sites is governed by the owners’ own terms and conditions.
RESULTS

Rapid Response reports are organized so that the higher quality evidence is presented first. Therefore, health technology assessment reports, systematic reviews, and meta-analyses are presented first. These are followed by randomized controlled trials, non-randomized studies, economic evaluations, and evidence-based guidelines.

Five systematic reviews, one randomized controlled trial, five non-randomized studies, two evidence-based guidelines, and two economic studies were identified regarding fecal bacteriotherapy for adult patients with recurrent *Clostridium difficile*. No health technology assessments were identified.

Additional references of potential interest are provided in the appendix.

**Health Technology Assessments**
No literature identified.

**Systematic Reviews and Meta-analyses**


**Randomized Controlled Trials**

Non-Randomized Studies


Economic Evaluations


Guidelines and Recommendations


PREPARED BY:
Canadian Agency for Drugs and Technologies in Health
Tel: 1-866-898-8439
www.cadth.ca
APPENDIX – FURTHER INFORMATION:

Case Study


Guidelines and Recommendation – Methodology Unknown


Review Articles


Additional References